PLAQUETEC LTD (‘PlaqueTec’) has announced the appointment of Dr Nick West as Chief Medical Officer.
Dr West is a Consultant Interventional Cardiologist at Papworth Hospital, Cambridge, the UK’s largest specialist Cardiothoracic Unit. He graduated in medicine from the University of Cambridge and undertook his Cardiology training at the John Radcliffe Hospital, Oxford; he previously undertook research towards his doctoral thesis in the field of endothelial biology at both the University of Oxford and Duke University, North Carolina.
He is a research-active clinician with extensive clinical trial experience in both industry-sponsored and investigator-initiated studies, with extensive track record of publication in intravascular imaging (IVUS, OCT), coronary physiology and novel medical devices, including bioabsorbable stents.
He has previously been Clinical Lead for Interventional Cardiology at Papworth, Deputy Chair of the British Cardiovascular Society Acute Cardiac Care Working Group and a longstanding member of the Guidelines & Clinical Practice Committee. He has also acted as an expert advisor to NICE, peer-reviews for journals and is a faculty member at national and international Cardiology meetings.
Dr West has consulted with PlaqueTec for a number of years as Medical Advisor, and was Principal Investigator for both PlaqueTec’s recent clinical study and the First-in-Man study that preceded it.
Commenting on his appointment, Tim Brears, CEO of PlaqueTec said: ‘We are delighted that Nick has joined us as CMO. He has significant experience in interventional cardiology and was integral to the development of PlaqueTec’s Liquid Biopsy System. He is an important addition to our team and will play a key role in the future development of our company.’
Nick West commented: ‘I am excited about joining the PlaqueTec management team. The company has developed a pioneering technology and the latest clinical study demonstrates that its approach significantly improves the resolution of coronary disease biomarkers. Preliminary data suggests that PlaqueTec’s technology has the potential to greatly benefit the development of new CAD therapies’.